Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Nektar Therapeutics (NKTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,890,466
  • Shares Outstanding, K 153,830
  • Annual Sales, $ 165,440 K
  • Annual Income, $ -153,520 K
  • 36-Month Beta 1.63
  • Price/Sales 18.03
  • Price/Cash Flow 0.00
  • Price/Book 33.63

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.00 +4.39%
on 04/13/17
24.88 -24.48%
on 03/29/17
-3.63 (-16.19%)
since 03/24/17
3-Month
11.41 +64.68%
on 01/31/17
24.88 -24.48%
on 03/29/17
+6.54 (+53.39%)
since 01/26/17
52-Week
11.41 +64.68%
on 01/31/17
24.88 -24.48%
on 03/29/17
+2.65 (+16.42%)
since 04/26/16

Most Recent Stories

More News
Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an analyst and investor event with clinical investigators on Saturday, June 3, 2017 at 6:00 pm CDT in Chicago, IL during the 2017 American...

NKTR : 18.79 (-3.09%)
Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and Clovis Oncology

NEW YORK, NY / ACCESSWIRE / April 10, 2017 / The iShares NASDAQ Biotechnology Index ETF gained 0.80 percent to close at 290.52, up 9.47 percent year-to-date. Nektar Therapeutics and Clovis Oncology have...

CLVS : 58.64 (+1.35%)
NKTR : 18.79 (-3.09%)
Look for Shares of Nektar Therapeutics to Potentially Rebound after Yesterday's 4.85% Sell Off

Nektar Therapeutics (NASDAQ:NKTR) traded in a range yesterday that spanned from a low of $19.65 to a high of $21.07. Yesterday, the shares fell 4.8%, which took the trading range below the 3-day low...

NKTR : 18.79 (-3.09%)
The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics

The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics

ESPR : 36.13 (-2.48%)
ARGS : 0.45 (-8.16%)
VRTX : 116.34 (-0.79%)
CDTX : 7.70 (+3.36%)
NKTR : 18.79 (-3.09%)
Nektar Therapeutics (NKTR) Up 57.2% Since Earnings Report: Can It Continue?

Nektar Therapeutics (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NKTR : 18.79 (-3.09%)
3 of the Best & Worst Performing Drug Stocks of Q1

Here is a look at 3 of the best and worst-performing drug stocks in the first quarter of 2017.

ESPR : 36.13 (-2.48%)
ARGS : 0.45 (-8.16%)
VRTX : 116.34 (-0.79%)
CDTX : 7.70 (+3.36%)
XENE : 4.00 (+2.56%)
NKTR : 18.79 (-3.09%)
Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced five preclinical data presentations for its immuno-oncology programs made at the American Association for Cancer Research (AACR) Annual Meeting 2017....

NKTR : 18.79 (-3.09%)
Shares of NKTR Up 70.3% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on March 2nd, 2017 at $14.06. In approximately 4 weeks, Nektar Therapeutics has returned 70.26% as of today's recent price of $23.93....

NKTR : 18.79 (-3.09%)
AstraZeneca Stock Rising in '17: What's Working in its Favor?

Shares of London-based pharma giant, AstraZeneca plc (AZN) have risen 13.4% this year so far, while the Zacks classified Large-Cap Pharma industry increased 6.4%.

AZN : 30.58 (+0.30%)
LLY : 80.96 (-0.30%)
AGN : 239.50 (+0.54%)
NKTR : 18.79 (-3.09%)
Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results

Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.

CTMX : 16.56 (-0.60%)
ARRY : 8.67 (-1.59%)
GILD : 68.22 (+1.64%)
REGN : 371.39 (-0.25%)
AMGN : 164.61 (-0.05%)
BIIB : 279.98 (-2.41%)
NKTR : 18.79 (-3.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists...

See More

Support & Resistance

2nd Resistance Point 19.94
1st Resistance Point 19.36
Last Price 18.79
1st Support Level 18.49
2nd Support Level 18.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.